Events

Quantum Technologies in Europe Conference
NOV
Wed
22
NOV
Thu
23

This was 1 year ago

Location

Madrid (Spain)

Programmes
Digital, Industry & Space

The Conference on Quantum Technologies in Europe is organised by the Agencia Estatal de Investigación (AEI) in collaboration with QuantERA. This conference aims to address the challenges facing the development of Quantum Technologies in terms of research and European policies to facilitate the delivery of scientific results to society and promote new opportunities to improve economic and social welfare. This event takes place as a satellite event of the Spanish Presidency of the EU.

This event will provide a unique opportunity for researchers, managers and practitioners of Quantum Technologies to share knowledge, discuss challenges and foster collaboration across Europe in this rapidly evolving field.

More info on the event website. The registration is obligatory and open until 2 November. Please note that once you have submitted your application, the organising committee will send the participation approvals by email.

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.